Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Clinical trial NCT03245424 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT03245424
Sponsor: Agios Pharmaceuticals, Inc.
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

Acute Myeloid Leukemia Relapsed Adult AML Relapsed Pediatric AML

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.